b'MRD TestsTest Name Indications for TestingNPM1 MRD Assaydentify tumor-specific markers for post-treatment Imonitoring Assay Type Monitor and evaluate disease recurrenceNext-Generation Sequencing (NGS)CLIA-validated assayMethod DescriptionTo track and identify previously detected NPM1 mutations in post-treatment follow-up samples, a multiplex master mix targeting exon 12 on the NPM1 gene is used to amplify DNA extracted from a patient sample. Next-generation sequencing of the PCR products is used to identify DNA sequences specific to previously identified mutations detected at diagnosis. Bioinformatics tools facilitate the detection of these specific sequences present at an allelic sensitivity level of 5x10 -5 . Interpretation TurnaroundSpecimenShippingSpecimen Time Requirements Conditions StabilityAn interpretive7 to 10 1-3 mL of peripheral Ambient or Cool; 2-8 C up report will bebusiness days blood in EDTA,do not freezeto 7 days priorissued indicating(peripheral blood orto testing whether NPM10.25-1 mL of bone marrow bone marrow) MRD was detected in EDTA1 g of previously Ambient or frozen onisolated DNAdry ice (isolated DNA) LabPMM Services Catalog 2021|39'